Inhibitors of coagulation

Haemophilia

Volumn 17, Issue 1, 2011, Pages 90-94

  Rangarajan, S ^a  

^a ST THOMAS HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ACTIVATED PROTHROMBIN COMPLEX; ANTICOAGULANT AGENT; APTAMER; ARGATROBAN; BLOOD CLOTTING FACTOR 8 INHIBITOR; BLOOD CLOTTING INHIBITOR; CYTOCHROME P450 2C9; DABIGATRAN; ENOXAPARIN; FONDAPARINUX; HEPARIN; HIRULOG; IDRAPARINUX; LOW MOLECULAR WEIGHT HEPARIN; PROTHROMBIN COMPLEX; RECOMBINANT BLOOD CLOTTING FACTOR 7A; RECOMBINANT NEMATODE ANTICOAGULANT PROTEIN C2; RIVAROXABAN; T LYMPHOCYTE RECEPTOR; UNCLASSIFIED DRUG; VITAMIN K GROUP; WARFARIN;

ANAPHYLAXIS; ARTICLE; BLEEDING; BLOOD CLOTTING; CELLULAR IMMUNITY; DEEP VEIN THROMBOSIS; DRUG CONTAMINATION; DRUG HALF LIFE; DRUG SAFETY; GENE MUTATION; HEMOPHILIA A; HEPARIN INDUCED THROMBOCYTOPENIA; HUMAN; INTERNATIONAL NORMALIZED RATIO; LUNG EMBOLISM; NONHUMAN; OSTEOPOROSIS; PARTIAL THROMBOPLASTIN TIME; PRIORITY JOURNAL; T LYMPHOCYTE; THROMBOSIS;

ANTICOAGULANTS; BLOOD COAGULATION DISORDERS; BLOOD COAGULATION FACTOR INHIBITORS; HUMANS;

EID: 79951894001     PISSN: 13518216     EISSN: 13652516     Source Type: Journal    
DOI: 10.1111/j.1365-2516.2010.02335.x     Document Type: Article

References (23)

1. Buller HR, Agnelli G, Hull RD, Hyers TM, Prins MH, Raskob GE. Antithrombotic therapy for venous thromboembolic disease: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Chest 2004; 126: 401S-28S.
2. Levine MN, Raskob G, Beyth RJ, Kearon C, Schulman S. Hemorrhagic complications of anticoagulant treatment: the Seventh ACCP Conference on Antithrombotic and ThrombolyticTherapy. Chest 2004; 126: 287S-310S.
3. Kessler CM. Current and future challenges of antithrombotic agents and anticoagulants: strategies for reversal of hemorrhagic complications. Semin Hematol 2004; 41: 44-50.
4. Crowther MA, Warkentin TE. Bleeding risk and the management of bleeding complications in patients undergoing anticoagulant therapy: focus on new anticoagulant agents. Blood 2008; 111: 4871-9.
5. Kishimoto TK, Viswanathan K, Ganguly T et al. Contaminated heparin associated with adverse clinical events and activation of the contact system. N Engl J Med 2008; 358: 2457-67.
6. Blossom DB, Kallen AJ, Patel PR et al. Outbreak of adverse reactions associated with contaminated heparin. N Engl J Med 2008; 359: 2674-84.
7. Guerrini M, Beccati D, Shriver Z et al. Oversulfated chondroitin sulfate is a contaminant in heparin associated with adverse clinical events. Nat Biotechnol 2008; 26: 669-75.
8. Hoppensteadt D, Wahi R, Adiguzel C et al. Contaminant in the recalled unfractionated heparin preparations: where is the problem? Clin Appl Thromb Hemost 2008; 14: 261-6.
9. Adiguzel C, Bansal V, Litinas E et al. Increased prevalence of antiheparin platelet factor 4 antibodies in patients may be due to contaminated heparin. Clin Appl Thromb Hemost 2009; 15: 145-51.
10. Bijsterveld NR, Moons AH, Boekholdt SM et al. Ability of recombinant factor VIIa to reverse the anticoagulant effect of the pentasaccharide fondaparinux in healthy volunteers. Circulation 2002; 106: 2550-4.
11. Lisman T, Bijsterveld NR, Adelmeijer J et al. Recombinant factor VIIa reverses the in vitro and ex vivo anticoagulant and profibrinolytic effects of fondaparinux. J Thromb Haemost 2003; 1: 2368-73.
12. Desmurs-Clavel H, Huchon C, Chatard B, Negrier C, Dargaud Y. Reversal of the inhibitory effect of fondaparinux on thrombin generation by rFVIIa, aCCP and PCC. Thromb Res 2009; 123: 796-8.
13. Eriksson BI, Borris LC, Friedman RJ et al. Rivaroxaban versus enoxaparin for thromboprophylaxis after hip arthroplasty. N Engl J Med 2008; 358: 2765-75.
14. Lassen MR, Ageno W, Borris LC et al. Rivaroxaban for thromboprophylaxis after total knee arthroplasty. N Engl J Med 2008; 358: 2776-85.
15. Kakkar AK, Brenner B, Dahl OE et al. Extended duration rivaroxaban versus short-term enoxaparin for the prevention of venous thromboembolism after total hip arthroplasty: a double-blind, randomised controlled trial. Lancet 2008; 372: 31-9.
16. Eriksson BI, Dahl OE, Rosencher N et al. Dabigatran etexilate versus enoxaparin for prevention of venous thromboembolism after total hip replacement: a randomised, double-blind, non-inferiority trial. Lancet 2007; 370: 949-56.
17. Eriksson BI, Dahl OE, Rosencher N et al. Oral dabigatran etexilate vs. subcutaneous enoxaparin for the prevention of venous thromboembolism after total knee replacement: the RE-MODEL randomized trial. J Thromb Haemost 2007; 5: 2178-85.
18. Lee AYY, Vlasuk GP. Recombinant nematode anticoagulant protein c2 and other inhibitors targeting blood coagulation factor VIIa/tissue factor. J Intern Med 2003; 254: 313-21.
19. Muller J, Freitag D, Mayer G, Potzsch B. Anticoagulant characteristics of HD1-22, a bivalent aptamer that specifically inhibits thrombin and prothrombinase. J Thromb Haemost 2008; 6: 2105-12.
20. Goudemand J, Rothschild C, Demiguel V et al. Influence of the type of factor VIII concentrate on the incidence of factor VIII inhibitors in previously untreated patients with severe hemophilia A. Blood 2006; 107: 46-51.
21. Gouw SC, van der Bom JG, van den Berg HM for the CANAL Study group. Treatment-related risk factors of inhibitor development in previously untreated patients with hemophilia A: the CANAL cohort study. Blood 2007; 109: 4648-54.
22. Ettinger RA, Papadopoulos GK, Moustakas AK, Nepom GT, Kwok WW. Allelic variation in key peptide-binding pockets discriminates between closely related diabetes-protective and diabetes-susceptible HLA-DQB106 alleles. J Immunol 2006; 176: 1988-98.
23. James EA, Kwok WW, Ettinger RA, Thompson AR, Pratt KP. T-cell responses over time in a mild hemophilia A inhibitor subject: epitope identification and transient immunogenicity of the corresponding self-peptide. J Thromb Haemost 2007; 5: 2399-407.